Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01925560 · ClinicalTrials.gov registry record · NA

Tolerance and Utilization of Agave Inulin in Healthy Adults

A NA study of Tolerance, sponsored by University of Illinois at Urbana-Champaign.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT01925560 is a NA study of Tolerance that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 30 participants, below the 51-participant average among 7 other Tolerance trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01925560, a NA study of Tolerance, has completed, sponsored by University of Illinois at Urbana-Champaign.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the tolerance and utilization of agave inulin. This will be accomplished through analyses of breath and fecal samples to quantify fermentation end-products- hydrogen, carbon dioxide, and methane will be measured in the breath, and short-chain fatty acids, ammonia, phenol, and indole will be measured in feces. Microbial populations will also be measured in fecal samples.

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Agave Inulin

Study Locations (1)

Illinois

  • University of Illinois - Urbana

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-01
Est. Completion 2014-05
Phase NA

What the Registry Record Tells You About NCT01925560

The ClinicalTrials.gov registry entry for NCT01925560 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 7 other Tolerance trials with a reported enrollment target (41% lower). The listed sponsor is University of Illinois at Urbana-Champaign, which has 129 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tolerance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01925560 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT01925560 about?

NCT01925560 is a clinical study titled "Tolerance and Utilization of Agave Inulin in Healthy Adults". The objective of this study is to assess the tolerance and utilization of agave inulin. This will be accomplished through analyses of breath and fecal samples to quantify fermentation end-products- hydrogen, carbon dioxide, and methane will be measured in the breath, and short-chain fatty acids, amm...

What is the current status of trial NCT01925560?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-01. Estimated completion is 2014-05.

What conditions does trial NCT01925560 study?

This clinical trial studies the following conditions: Tolerance.

What interventions are being tested in trial NCT01925560?

The interventions under investigation include: Placebo (OTHER), Agave Inulin (OTHER).

Who is sponsoring clinical trial NCT01925560?

This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01925560 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tolerance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.